Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by Wino115on Apr 21, 2022 2:38pm
188 Views
Post# 34621298

Pattern is back

Pattern is back

By my reckoning, the seller has around 85k shares left.  Todays pattern is what they were doing before.  Small lots every 15 minutes or so regardless of level or market depth.  Very much an algo approach to exiting at a day or week average.  May take another 10-15 trading days with the low vols.  Probably perfectly timed exit at lows, just in time for the premiere TH1902 data set for what they learned in the dosage portion!  


FYI, THTX has been sensible with the IND they will initially go for no what INDs likely would follow.  The Mackie analyst seems to think it will be Ovarian and Endometrial.  I don't know if that's his own guess, from AACR papers or from mgmt. Ovarian is a tough one, but hurdle is low.  A good comp would Immunogen ADC in Phase 2 or maybe 3 now.  Their market cap went up around $750mil coming out of the 1b trial, and in to 2.  ORR is around 30% (almost all partial)  and PFS 6 months.  But it had some decent side effects (even a trial related death).  

So you could say the market valued a decent ADC in Ovarian coming out of its initial human efficacy trial as worth around that $600-750 million level.  Their mkt cap is $1.1 bil as they have a few other early stage oncology drugs.  

For endometrial, I think Keytruda gets a lot of that along with a SeaGen drug so harder to put a mkt value on that one line now.  It's a smaller market overall.  

I still hope TNBC and melanoma will also be strong indications for TH1902.  Those are huge markets.

<< Previous
Bullboard Posts
Next >>